Anti-CTLA-4 inhibitor-containing regimen was also significantly associated with severity; 13 patients under such regimen developed CTCAE grade 4 hepatitis (13/45 vs. 9/71 for non-CTLA-4-treated patients, p <0.001). This evidence concerns the gene CTLA4 and hepatitis A virus infection.